CD274 and renal cell carcinoma: Post-approval era: Any of the following anti-PD-(L)1 agents delivered alone or in combination with other pharmacological treatments• NSCLC: atezolizumab, cemiplimab, durvalumab, nivolumab, or pembrolizumab• RCC: avelumab, nivolumab, or pembrolizumab• Melanoma: atezolizumab, nivolumab, or pembrolizumab